SavedAdd your journal

Journals / Journal of Surgery and Medicine / 2021 / Cilt: 5 - Sayı: 8

Incidence and risk factors of nephrotoxicity associated with intravenous colistin use in the intensive care unit

Ökkeş Hakan MİNİKSAR
Erol TOY
Pages
750–754
Publication Date
2021-08-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In those with NT, diabetes mellitus, chronic obstructive pulmonary disease, and coronary artery disease were significantly more common (P

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aim: The most serious side effect of colistin therapy is nephrotoxicity.
📊
Key Findings & Data:Methods: This retrospective cohort study was conducted by examining the files of 100 patients who were hospitalized in the ICU and received intravenous colistin therapy.
💡
Conclusion & Impact:In those with NT, diabetes mellitus, chronic obstructive pulmonary disease, and coronary artery disease were significantly more common (P
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Colistin · Nephrotoxicity · Intensive care unit

Abstract

Background/Aim: The most serious side effect of colistin therapy is nephrotoxicity. This study aimed to investigate the incidence of nephrotoxicity (NT) due to intravenous colistin and determine the associated risk factors in critically ill patients in the intensive care unit (ICU). Methods: This retrospective cohort study was conducted by examining the files of 100 patients who were hospitalized in the ICU and received intravenous colistin therapy. According to the RIFLE criteria, the patients were divided into two groups as those with and without nephrotoxicity. The clinical characteristics of the patients were compared between the groups and the risk factors associated with nephrotoxicity were determined by multivariate linear logistic regression analysis. Results: The mean age, mean length of stay in the ICU, and mortality rate of 44 patients included in the study were 68±16.36 years, 77.14 (83.03) days, and 56.8%, respectively. NT developed in 22 (50%) patients during colistin therapy. In those with NT, diabetes mellitus, chronic obstructive pulmonary disease, and coronary artery disease were significantly more common (P

🔖

Cite This Article

MİNİKSAR, Ö. H., TOY, E. (2021). Incidence and risk factors of nephrotoxicity associated with intravenous colistin use in the intensive care unit. Journal of Surgery and Medicine, Cilt: 5 - Sayı: 8, 750–754. https://ajindex.com/articles/779871

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Gunay E, Kaya S, Baysal B, Yuksel E, Arac E. Evaluation of prognosis and nephrotoxicity in patients treated with colistin in intensive care unit. Ren Fail. 2020;42:704–9
  2. Falagas ME, Fragoulis KN, Kasiakou SK, Sermaidis GJ, Michalopoulos A. Nephrotoxicity of intravenous colistin: A prospective evaluation. Int J Antimicrob Agents. 2005;26:504–7
  3. Kılınç Ç, Ulutaş KT, Akçimen B, Çelik L, Duran N. Colistin administration for extensive drug-resistant Pseudomonas aeruginosa pneumonia in intensive care unit: case report. Cukurova Med J. 2016;41:178
  4. Hartzell JD, Neff R, Ake J, Howard R, Olson S, Paolino K, et al. Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center. Clin Infect Dis. 2009;48:1724–8
  5. Doshi NM, Mount KL, Murphy C V. Nephrotoxicity associated with intravenous colistin in critically ill patients. Pharmacotherapy 2011;31:1257–64
  6. Ordooei Javan A, Shokouhi S, Sahraei Z. A review on colistin nephrotoxicity. European Journal of Clinical Pharmacology. 2015;71:801-10
  7. Çiftçi A, Izdes S, Altintas ND. Factors determining nephrotoxicity and mortality in critical care patients receiving colistin. J Infect Dev Ctries. 2017;11:912–8
  8. Talib S, Sharif F, Manzoor S, Yaqub S, Kashif W. Charlson comorbidity index for prediction of outcome of acute kidney injury in critically ILL patients. Iran J Kidney Dis. 2017;11:115–23
  9. Kelesidis T, Falagas ME. The safety of polymyxin antibiotics. Expert Opin Drug Saf. 2015;14:1687–701
  10. Balkan II, Dogan M, Durdu B, Batirel A, Hakyemez IN, Cetin B, et al. Colistin nephrotoxicity increases with age. Scand J Infect Dis. 2014;46:678–85
  11. Korkmaz Ekren P, Töreyin ZN, Berk Takir H, Kalamanoğlu Balci M, Gaygisiz Ü, Gürsel G, et al. Evaluation of nephrotoxicity and prognosis in patients treated with colistin due to hospital-acquired pneumonia. Tuberk Toraks. 2017;65:271–81
  12. Shariatmaghani S, Shariatmaghani SS, Sedaghat A, Najafi MN, Moghaddam AB. Colistin-associated acute kidney injury in intensive care unit patients: Significance of other confounding factors. Int Res J Med Med Sci. 2019;7:91–8
  13. Arslan Zİ, Özbudak E, Türkyılmaz N, Cesur S, Alparslan V, Mirhanoğulları AF, et al. Evaluation of the Use of Colistin on Nephrotoxicity and Mortality in the Intensive Care Unit. Turkiye Klin J Anesthesiol Reanim. 2015;13:21–4
  14. Kim J, Lee KH, Yoo S, Pai H. Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J